학술논문

Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study
Document Type
Report
Source
Clinical and Translational Allergy. July 17, 2019, Vol. 9 Issue 1
Subject
Peanut allergy -- Research
Platelet activating factor -- Research
Immune response -- Research
Antihistamines -- Dosage and administration
Anaphylaxis
Food hypersensitivity
Allergy
Asthma
Hives (Disease)
Histamine
Endothelium
Phospholipids
Enzyme-linked immunosorbent assay
Enzymes
Language
English
ISSN
2045-7022
Abstract
Background Platelet activating factor (PAF) is an endogenous, active phospholipid released from inflammatory cells, platelets, and endothelial cells, and is involved in the regulation of immune responses. Degradation of PAF by PAF acetylhydrolase (PAF-AH) has been shown to be associated with anaphylaxis, asthma, and peanut allergy. The purpose of this study was to investigate relationships among clinical parameters, including urticaria severity and treatment responsiveness, and PAF and PAF-AH levels in sera from patients with chronic spontaneous urticaria (CSU). Methods Serum PAF and PAF-AH levels were measured by enzyme-linked immunosorbent assay in 283 CSU patients and 111 age- and sex-matched, healthy normal controls (NCs). Urticaria severity was evaluated by urticaria activity score over 7 days (UAS7). Within 3 months after measuring PAF levels, patients whose urticaria was not controlled by antihistamine treatment were classified as histamine receptor 1 antagonist (H1RA) non-responders. Results Serum PAF levels were significantly higher in CSU patients than in NCs (median 4368.9 vs. 3256.4 pg/ml, p = 0.015), while serum PAF-AH levels were significantly lower in CSU patients (105.6 vs. 125.7 ng/ml, p = 0.001). H1RA non-responders had higher levels of PAF in their sera than H1RA responders. A generalized linear model revealed that a higher UAS7 score (odds ratio 1.023, p = 0.024) and a PAF level [greater than or equai to] 5000 pg/ml (1.409, p < 0.001) were significant predictors of a poor response to H1RA treatment. Conclusions Compared with NCs, CSU patients, particularly those with H1RA refractoriness, showed significant increases in serum PAF levels and decreases in PAF-AH. Therapies modulating PAF and PAF-AH levels could be effective in patients with CSU refractory to antihistamines. Keywords: Platelet activating factor, Platelet activating factor acetylhydrolase, Chronic spontaneous urticaria
Author(s): Bastsetseg Ulambayar[sup.1] , Eun-Mi Yang[sup.1] , Hyun-Young Cha[sup.1] , Yoo-Seob Shin[sup.1] , Hae-Sim Park[sup.1] and Young-Min Ye[sup.1] Background Platelet activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a bioactive phospholipid that plays [...]